Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic - Seite 2

"Our initial studies have demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated the ability to extract and profile microRNAs from thyroid FNAs. The access to IMTM's thyroid cancer samples and translation research should enhance and accelerate the larger validating studies we have underway, as we plan for a third quarter 2015 launch of our thyroid assay in the U.S.," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "This partnership represents a good opportunity to work with distinguished partners on a high-value thyroid diagnostic. We have been pleased with our interactions with EATRIS and impressed with their smooth and efficient international collaboration process."

"This partnership is a prime example of how EATRIS is paving the way to improved product development by facilitating collaborations that combine access to innovative translational research infrastructure and industry expertise. This is a great time to be part of EATRIS as patient outcomes are within reach," noted Anton Ussi, Head of Operations at EATRIS. 

About EATRIS and ERIC
The European Advanced Translational Research Infrastructure is comprised of leading academic groups and institutions, in eight countries, which provide access to innovative translational research infrastructure and expertise. They leverage their state-of-the-art facilities and knowledge to reduce risks within translational research across Europe, while increasing productivity. Participating institutes are selected and continuously monitored on the basis of the available infrastructure, expertise and quality standards which comply with current European pharmaceutical regulations, laws and guidelines. As a European Research Infrastructure (ERIC), EATRIS headquarters provide 'Coordination & Support' activities in organizing one-stop access to over 70 research centres of excellence across Europe. For more information, please visit www.eatris.eu. 

About IMTM
The Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University in Olomouc, is the leading translation medicine institute in the Czech Republic and national node for EATRIS. The IMTM's mission is basic and translational biomedical research with the goal to better understand the underlying causes of human diseases, mostly cancer and infections, and to develop future human medicines, medical devices and diagnostics. For more information, please visit https://www.imtm.cz.